期刊文献+

紫杉醇在青光眼滤过手术中抗增殖作用的实验研究 被引量:1

Experimental study ofantiproliferative effect ofpaclitaxel on glaucoma filtration surgery
原文传递
导出
摘要 目的观察紫杉醇(paclitaxel)对成纤维细胞活性的影响。方法在兔实验性小梁切除术中,对照组、实验Ⅰ组、实验Ⅱ组巩膜瓣下分别应用0.2mg/ml丝裂霉素C(MMC)、0.3mg/ml紫杉醇、0.3mg/ml紫杉醇5min,实验Ⅱ组术后第3、6、9天结膜下注射紫杉醇30μg。术后第4、7、14、28天通过病理组织学观察滤过道开放情况、增殖细胞核数量及胶原形成情况。结果术后第7、14、28天实验Ⅰ组比对照组PCNA阳性细胞数差异无统计学意义(P〉O.05),实验Ⅱ组比对照组PCNA阳性细胞数少,差异有统计学意义(P〈0.05);实验Ⅱ组比对照组滤过道开放比率高;实验Ⅱ组在滤过道处形成的Ⅲ型胶原少。结论紫杉醇和丝裂霉素C同样可以有效的抑制成纤维细胞的增殖;紫杉醇在术中及术后联合应用,其抗增殖能力增强。 Objective To investigate the effects of paclitaxel on the fibroblast replication activity. Methods During trabeculectomy in rabbits eyes, 0.2mg/ml mitomycinC (MMC), 0.3mg/ml paclitaxel, 0.3mg/ml paclitaxel were applied in scleral bed for 5 minutes in control group,experimental group Ⅰ , experimental group Ⅱrespectively. Paclitaxel 30μ g were injected subconjunctiva at days 3,6 and 9 following surgery in experimental group Ⅱ. The following parameters were recorded at days 4,7,14,28 after surgery: filtration passage by histopathology,the number of PCNA positive cells by immunohistochemical staining, collagen formation by 2.4.6-Trinitrophend-Sirius Red F3B. Result The percentage of opened filtration passage was lower in the experimental group I than the control group.But it was higher in experimental group II than control group at 14,28 days after surgery.The difference of the number of positive cells was significant between the experimental group Ⅱ and the control group at 7,14,28 days after surgery (P 〈0.05). At 14 days, type Ⅲ collagen is crassic and dense in the control group,loose in the experimental group Ⅰ ,piecemeal in the experimental group Ⅱ .Conclusion Paclitaxel is equal to MMC in inhibiting proliferation of fibroblast. Paclitaxel is stronger in inhibiting proliferation of fibroblast by combined using it intraoperatively and postoperatively.
出处 《中国实用眼科杂志》 CSCD 北大核心 2008年第8期870-872,共3页 Chinese Journal of Practical Ophthalmology
关键词 紫杉醇 滤过手术 增殖细胞核抗原 Paclitaxel filtration surgery Proliferative cell nucleus antigen Rabbit
  • 相关文献

参考文献5

  • 1Daniels SA,Coonley KG,Yoshizumi MO.Taxel treatment of experimental proliferative vitreoretinopathy.Graefes Arch Clin Exp Ophthalmol, 1990,228(6):513-6.
  • 2Francesco M,Von Bockxmeer,Clayton E,et al.Taxol for the treatment of proliferative vitreoretinopathy.Invest Ophthalmol Vis Sci,1985,26: 1140-1147.
  • 3Markan M,Rowinsky E,Hakes T.Phase I trial of intraperitoneal taxol:a gynecologic oncology group study.J Clin Oncol,1992,10:1485-1497.
  • 4Jampel HD, Moon JI. The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J Glaucoma, 1998,7(3):170-7.
  • 5Jampel HD, Thibauh D, Leong KW,et al. Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis Sci, 1993,34(11):3076-83.

同被引文献14

  • 1王方聚,王淑静,朱永峰.紫杉醇联合卡铂治疗小细胞肺癌的临床效果[J].实用医药杂志,2005,22(2):129-129. 被引量:5
  • 2杨国华,张晓玮,陈静琪,李润婷.难治青光眼术中使用红比霉素的效果[J].眼科研究,1995,13(4):258-261. 被引量:5
  • 3李俊英,吴欣怡.紫杉醇用于兔青光眼手术的实验研究[J].山东大学学报(医学版),2006,44(11):1164-1166. 被引量:2
  • 4倪雪峰,吴昌平,王赫.TCF方案与PF方案治疗晚期食管癌的临床研究[J].临床肿瘤学杂志,2007,12(7):509-511. 被引量:6
  • 5Ishikawa H,Nakanisi T, Nawa A, Suzuki Y, Kuzuya K. 3-hour in infusion of single-agent paclitaxel for recurrent ovarian cancer [ J ] . Int J Clin Oncol,2001,5( 3 ) :128-131.
  • 6Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol,2003,21 (6) :976-983.
  • 7Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W, et al. Synergy of 5-aza-2' -deoxycytidine (DAC) and paclitaxel in both androgendependent and-independent prostate cancer cell lines[ J ]. Cancer Lett,2009,278( 1 ) :82-87.
  • 8Stone GW,Midei M,Newman W,Sanz M,Hermiller JB,Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease:a randomized trial[ J]. JAMA ,2008,299(16) : 1903-1913.
  • 9Kmcoff MW, Kereiakes D J, Petersen JL, Mehran R, Hasselblad V, Lansky A J, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiprolfferative for Restenosis ) Ⅱ study [ J ]. J Am Coll Cardiol,2008 ,51 (15) :1543-1552.
  • 10Raccor BS, Vogt A, Sikorski RP, Madiraju C, Balachandran R, Montgonmery K,et al. Cell-based and biochemical structure-activity analyses of analogs of the microtubule stabilizer dictyostatin [ J ]. Mol Pharmacol , 2008,73 ( 3 ) :718 -726.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部